Core Insights - Hualan Vaccine's stock price decreased by 2.02% on November 20, trading at 22.34 CNY per share with a market capitalization of 13.43 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.63%, but a recent decline of 5.62% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Hualan Vaccine reported a revenue of 806 million CNY, a year-on-year decrease of 15.81%, and a net profit attributable to shareholders of 132 million CNY, down 50.51% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.037 billion CNY, with 957 million CNY distributed over the past three years [3] Shareholder Structure - As of October 20, 2025, the number of shareholders for Hualan Vaccine stands at 17,000, with an average of 35,332 circulating shares per person [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., which has reduced its holdings by 43,990 shares [3]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant growth this year, with an 81.11% increase in share price, indicating strong market performance and investor interest [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has distributed a total of 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai Zhongxin Livestock Breeding ETF, which holds 25.0398 million shares, and Hong Kong Central Clearing Limited, holding 21.1968 million shares, both showing increases in their holdings [3].

Core Viewpoint - The stock price of Wens Foodstuff Group Co., Ltd. has experienced fluctuations, with a current price of 17.69 CNY per share, reflecting a year-to-date increase of 10.48% but a recent decline over the past five and twenty trading days [1] Financial Performance - For the period from January to September 2025, Wens achieved a revenue of 75.82 billion CNY, representing a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased by 17.98% to 5.26 billion CNY [2] - Cumulative cash dividends since the company's A-share listing amount to 30.11 billion CNY, with 6.93 billion CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Wens was 81,100, a decrease of 10.94% from the previous period. The average number of circulating shares per person increased by 12.11% to 73,543 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 144 million shares, an increase of 5.50 million shares compared to the previous period, while E Fund's ChiNext ETF reduced its holdings by 19.09 million shares to 113 million shares [3] Business Overview - Wens Foodstuff Group, established on July 26, 1993, and listed on November 2, 2015, primarily engages in the breeding and sale of meat chickens and pigs. The revenue composition includes 65.67% from pig breeding, 30.34% from chicken breeding, and smaller contributions from other sectors [1]

Company Overview - KQ Bio, established on January 11, 2001, and listed on September 22, 2020, is located in Wuhan, Hubei Province. The company specializes in the research, production, and sales of veterinary biological products and animal epidemic prevention technology services [1][2]. - The main business revenue composition includes 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - For the period from January to September 2025, KQ Bio achieved a revenue of 738 million yuan, representing a year-on-year growth of 10.87%. The net profit attributable to the parent company was 338 million yuan, showing a year-on-year increase of 29.62% [2]. - Cumulative cash dividends since the A-share listing amount to 711 million yuan, with 488 million yuan distributed over the past three years [3]. Stock Performance - As of November 17, KQ Bio's stock price was 16.24 yuan per share, with a market capitalization of 7.57 billion yuan. The stock has increased by 17.15% year-to-date but has seen a decline of 0.43% over the last five trading days, 6.13% over the last 20 days, and 5.80% over the last 60 days [1]. - The number of shareholders as of September 30 was 9,713, an increase of 2.41% from the previous period, while the average circulating shares per person decreased by 2.36% to 47,990 shares [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 5.5731 million shares, an increase of 3.2155 million shares from the previous period [3].

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant price movements, with a year-to-date increase of 58.86% and a recent trading volume indicating active market participation [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average number of tradable shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional holdings include the Guotai Zhongzheng Livestock Breeding ETF, which is the fourth-largest shareholder with 25.0398 million shares, an increase of 9.0897 million shares from the previous period [3].

Core Viewpoint - The stock of Wens Foodstuff Group Co., Ltd. has shown a positive trend with a 14.23% increase year-to-date, despite a slight decline in recent trading days [1][2]. Financial Performance - For the period from January to September 2025, Wens achieved a revenue of 758.17 billion yuan, reflecting a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased by 17.98% to 52.56 billion yuan [2]. - Cumulatively, the company has distributed 301.10 billion yuan in dividends since its A-share listing, with 69.35 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wens was 81,100, a decrease of 10.94% from the previous period. The average number of tradable shares per shareholder increased by 12.11% to 73,543 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 144 million shares, an increase of 5.50 million shares compared to the previous period. Conversely, E Fund's ChiNext ETF reduced its holdings by 19.09 million shares to 113 million shares [3]. Stock Market Activity - On November 10, Wens' stock price rose by 2.01% to 18.29 yuan per share, with a trading volume of 724 million yuan and a turnover rate of 0.67%. The total market capitalization reached 121.7 billion yuan [1]. - The net inflow of main funds was 32.71 million yuan, with significant buying and selling activities recorded [1].

Core Viewpoint - Kanghua Biotech's stock has shown significant growth this year, with a 51.82% increase, despite a decline in revenue and net profit for the first nine months of 2025 [1][2]. Group 1: Stock Performance - On November 7, Kanghua Biotech's stock rose by 2.01%, reaching 81.29 CNY per share, with a trading volume of 2.09 billion CNY and a turnover rate of 2.21% [1]. - The company's market capitalization stands at 10.563 billion CNY [1]. - Year-to-date, the stock has increased by 51.82%, with a 5.24% rise over the last five trading days, 5.57% over the last 20 days, and 4.03% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Kanghua Biotech reported a revenue of 840 million CNY, a year-on-year decrease of 20.78%, and a net profit attributable to shareholders of 189 million CNY, down 53.41% year-on-year [2]. - The company has distributed a total of 686 million CNY in dividends since its A-share listing, with 462 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 18,300, a rise of 6.13%, while the average number of circulating shares per person decreased by 8.10% to 6,502 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 1.1826 million shares, marking its entry as a new shareholder [3]. - The Southern CSI 1000 ETF is the seventh largest shareholder with 850,600 shares, having decreased its holdings by 11,000 shares compared to the previous period [3].

Core Viewpoint - TianKang Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Group 1: Stock Performance - On November 7, TianKang Biological's stock rose by 2.03%, reaching 7.53 CNY per share, with a trading volume of 80.02 million CNY and a turnover rate of 0.79% [1]. - The stock has increased by 18.96% year-to-date, with a 2.03% rise in the last five trading days, a 2.46% decline over the last 20 days, and a 16.74% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, TianKang Biological reported a revenue of 13.61 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to shareholders decreased by 27.20% to 412 million CNY [2]. - The company has distributed a total of 1.89 billion CNY in dividends since its A-share listing, with 598 million CNY distributed in the last three years [3]. Group 3: Business Overview - TianKang Biological, established on December 28, 2000, and listed on December 26, 2006, is based in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [1]. - The revenue composition of the company includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Group 4: Shareholder Information - As of October 31, the number of shareholders for TianKang Biological was 58,000, a decrease of 3.11% from the previous period, with an average of 23,548 circulating shares per shareholder, an increase of 3.21% [2]. - Notable institutional holdings include Guotai Zhongzheng Livestock Breeding ETF as the fifth-largest shareholder with 24.30 million shares, and Hong Kong Central Clearing Limited as the seventh-largest shareholder with 15.03 million shares, marking a new entry [3].

Core Viewpoint - Tianbang Food's stock has experienced a decline in recent trading sessions, with a notable drop in both revenue and net profit year-on-year, indicating potential challenges in the company's financial performance [1][2]. Group 1: Stock Performance - On November 7, Tianbang Food's stock fell by 2.07%, trading at 2.84 CNY per share, with a total market capitalization of 6.31 billion CNY [1]. - The stock has increased by 1.79% year-to-date, but has seen declines of 1.39% over the last five trading days, 2.07% over the last twenty days, and 7.19% over the last sixty days [1]. - The company has appeared on the trading leaderboard once this year, with a net buy of 20.53 million CNY on May 8 [1]. Group 2: Financial Performance - For the period from January to September 2025, Tianbang Food reported a revenue of 6.72 billion CNY, a year-on-year decrease of 5.98%, and a net profit attributable to shareholders of 260 million CNY, down 80.65% year-on-year [2]. - The company has distributed a total of 1.185 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [2]. Group 3: Business Overview - Tianbang Food, established on September 25, 1996, and listed on April 3, 2007, is primarily engaged in pig farming and pork product processing, with revenue contributions of 63.82% from pig farming, 33.25% from food processing, 2.85% from feed products, and 0.08% from other sources [1]. - The company operates within the agricultural sector, specifically in the pig farming industry, and is associated with various concepts including the metaverse, pork, prepared dishes, animal vaccines, and avian influenza medications [2].

Core Viewpoint - The stock price of Reap Bio fell by 2.09% on November 3, with a trading volume of 140 million yuan and a market capitalization of 9.806 billion yuan [1] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone. The company specializes in the research, production, and sales of veterinary biological products, chemical drugs, biological agents, traditional veterinary medicine, natural plant medicines, premixed feeds, feed additives, and veterinary raw materials [2] - The main business revenue composition is 77.95% from animal protection and 22.05% from the pet supply chain [2] - As of October 20, 2023, the number of shareholders is 25,000, with an average of 13,398 circulating shares per person [2] Financial Performance - For the period from January to September 2025, Reap Bio achieved a revenue of 2.544 billion yuan, representing a year-on-year growth of 45.66%. The net profit attributable to the parent company was 362 million yuan, with a year-on-year increase of 48.04% [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3] Shareholding Structure - As of September 30, 2025, the sixth largest circulating shareholder is the Guotai Zhongzheng Livestock Breeding ETF, holding 6.3383 million shares, an increase of 2.3571 million shares from the previous period. The Hong Kong Central Clearing Limited is the tenth largest shareholder, holding 3.6017 million shares, a decrease of 2.9711 million shares from the previous period [3]